You are here

Black Ant King tablets

Safety advisory

5 June 2013

Black Ant King tablets pose a serious risk to your health and should not be taken.

Black Ant King front of packagingBlack Ant King back of packagingBlack Ant King back of blister packBlack Ant King frontt of blister pack

The Therapeutic Goods Administration (TGA) has tested Black Ant King tablets and found that:

  • it contains the undeclared substance sildenafil
  • consumers are advised that sildenafil is a prescription-only substance (which is the active ingredient in the medicine Viagra).

The supply of Black Ant King tablets is illegal.

Black Ant King tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia have bought the product online.

Information for consumers

  • Stop taking Black Ant King tablets and take any remaining tablets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Service (Customs) to help stop future shipments of Black Ant King tablets from entering Australia.

If Black Ant King tablets are found at the border by Customs they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products